Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 FY- Text added to 2021 FY
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
acknowledged, Alimta, Cambridge, Companyand, dispute, epithelial, ID, inline, Kirsten, LabCentral, MA, mesenchymal, rat, resolution, revisit, sarcoma, SBA, viral, wasa, yearsfor
Removed:
afatinib, aimed, Alecensa, Alunbrig, apalutamide, AstraZenica, asymptomatic, atezolizumab, Avastin, Boehringer, BRAF, brigatinib, certinib, contrast, create, CRPC, developmental, disqualify, enzalutamide, Erleada, exhibiting, gemcitabine, Gemzar, Gilotrif, improperly, Iressa, Jevtana, Keytruda, Lilly, necitumumab, osimertinib, permitted, pharmacokinetic, Portrassa, potent, scaffold, Selective, Seniority, Tagrisso, Takeda, Tarceva, Taxotere, Tecentriq, Trexall, XRL, Xtandi, Zykadia, Zytiga
Valuein 2020 FY filing- Value in 2021 FY filing
Original filings
Filing view